Tagged with

Hong Kong Hong Kong recently announced its first-ever Five-Year Plan, a sign of closer alignment with mainland China. With a clearer roadmap to 2030, what are the implications for biopharma?   A First FYP Even since returning to Chinese control in 1997, Hong Kong has maintained its role as a trading hub…

USA The National Health Council represents nearly 200 member organizations, with patient groups required by its bylaws to hold the majority of governance and decision-making roles. Five years after taking the helm as CEO, Randall “Randy” Rutta oversees an association formed more than a century ago to ensure the patient experience…

Korea Brad Edwards became the first foreign general manager in the Lundbeck Korea’s 23-year history last year, joining from a background at Shire and Takeda across Australia and Singapore. He spoke to us about steering the company’s shift from psychiatry toward neuro-rare disease, the upcoming launch of its new migraine treatment,…

Europe Behind every dose of heparin lies a complex industrial process in which access to raw materials, traceability and manufacturing expertise are as important as the medicine itself. Luis Solera, CEO of Bioiberica, examines how the Barcelona-based group has turned these capabilities into a global business spanning human, animal and plant…

Spain With a huge investment from AstraZeneca at its core, can the Spanish city of Barcelona really now rival more established European life sciences ecosystems?   Back in 2023, Barcelona was a somewhat surprising choice for AstraZeneca’s new global R&D hub. The Catalan capital, Spain’s second largest city, lacks both the…

China Like most founders, my dream is to bring one of our own drugs to market and see patients genuinely benefit from our inventions Built on deep expertise in oligonucleotide chemistry, Leaderna Therapeutics is advancing a new generation of siRNA medicines for chronic diseases, with programmes spanning hypertension, dyslipidaemia and obesity.…

France We need to raise our voice and say: look at us too, there are also mid-sized pharma companies out there looking for something different In conversation at BIO 2026 in San Diego, Frédéric Scaerou, Head of Global Business Development at Servier, explains why the company is staying disciplined rather than…

China Strong efficacy data attracts collaborators, but confidence shaken by other companies’ weaker results holds the whole field back Regend Therapeutics was founded in 2015 by Dr Ting Zhang and her husband, Professor Wei Zuo, to move stem cell research out of the lab and into patients. The company went on…

LatAm Real-world evidence (RWE) is now a regular part of health technology assessment in Europe and North America. In this article, first published in ISPOR’s Value & Outcomes Spotlight (July/August 2026), authors from six of ISPOR’s Latin American chapters argue that the region has plenty of health data. What it lacks…

Germany Germany is one of Takeda’s largest markets, a major manufacturing base and an important clinical research location, yet its long-standing reputation for rapid access to innovation is coming under pressure. GM Germany Dr Ingeborg Borgheim discusses how Takeda is preparing its German operations for a new generation of launches, where…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Asieris’ $250M deal with Theramex for APL-1702 (CEVIRA®), MicuRx’s $974M collaboration with ClearideBio for MRX-23 and ADC programs, and Defand’s partnership with Roche on molecular glue degraders. Other updates feature DualityBio’s IPO progress, Akeso’s Phase III NSCLC trial, and…

Korea Korea, the world’s 13th-largest pharma market, is rolling out its biggest reform to pharma pricing in a generation, slashing what it pays for generics and using the savings to get innovative medicines to patients faster and at better prices. The same squeeze on generic margins, combined with new rewards for…